Abstract: To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug. The invention provides a 3?-ethynylcytidine derivative represented by formula (1): (wherein X represents a (substituted) alkylcarbonyl group, a (substituted) alkoxycarbonyl group, or a hydrogen atom; one of Y and Z represents a hydrogen atom or a group represented by (R1)(R2)(R3)Si— and the other represents a group represented by (R4)(R5)(R6)Si—; and R1, R2, R3, R4, R5, and R6 each represent a (substituted) alkyl group, a (substituted) cyclic alkyl group, or a (substituted) aryl group) or a salt thereof.

Abstract: To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent a lower alkyl group, an imino group, a hydroxyl group, a hydroxymethyl group, a methanesulfonyloxy group, or an amino group; an amidinothio group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group; a guanidino group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group or a cyano group; a lower alkylamidino group; or a 1-pyrrolidinylmethyl group) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil.

Abstract: The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1): wherein R1, R2, and R4 may be the same or different from one another and represent a hydrogen atom, hydroxy group, or protected hydroxy group, excluding the case where R1, R2, and R4 are all a hydrogen atom, and R3 represents a halogen atom, amino group, carboxyl group, carbamoyl group, cyano group, nitro group, alkyl group having 1 to 6 carbon atoms, alkenyl group having 2 to 6 carbon atoms, or carbonyl group containing an alkoxy group having 1 to 6 carbon atoms).

Abstract: The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. A radiotherapy enhancer comprising (A) tegafur and (B) gimeracil.

Abstract: A DNA array for measuring sensitivity to an antimetabolite-type anticancer agent or a combined use of such an anticancer agent and another anticancer agent, characterized by including at least 13 types of target gene fragments, involving at least two types of genes selected from each of the following groups: nucleic acid metabolism-associated enzyme genes, gene repair-associated enzyme genes, drug resistance-associated factor genes and housekeeping genes, wherein these gene fragments have been selected by the following steps 1) and 2) and immobilized on a substrate; 1) a step of selecting fragments having high specificity for target genes by searching the homology with the use of databases; and 2) a step of performing Northern hybridization against RNA obtained from tumor cells with the use of the fragments selected in the step 1) as probes to thereby confirm the specificity for the target genes.

Abstract: The present invention provides: an anti-HIV composition comprising at least one member selected from the group consisting of trifluridine and derivatives thereof, and a pharmaceutically acceptable carrier; an anti-HIV composition comprising (a) at least one member selected from the group consisting of trifluridine and derivatives thereof, (b) a thymidine phosphorylase inhibitor, and a pharmaceutically acceptable carrier; and a composition for potentiating the anti-HIV activity of trifluridine and derivatives thereof, comprising a thymidine phosphorylase inhibitor and a pharmaceutically acceptable carrier.

Abstract: This invention relates to a method for immunologically measuring human thymidylate synthase with an anti-human thymidylate synthase antibody, wherein as the antibody, at least an anti-human thymidylate synthase polyclonal antibody immobilized on an insoluble matrix is used; a method for evaluating sensitivity of cancer cells to a fluoropyrimidine antitumor drug from the results of the measurement by the measuring method; and a human thymidylate synthase measuring kit comprising an insoluble matrix with at least one anti-human thymidylate synthase polyclonal antibody immobilized thereon. By a simple immunological measuring method, human TS in a sample can be measured with high sensitivity.

Abstract: Non-human animals deficient in a function of a uridine phosphorylase gene on a chromosome, and their offspring. These non-human animals and their offspring make it possible to elucidate pathologic functions and activities of nucleic acid dysbolism and the like and also to predict utility of pyridine nucleoside antimetabolites in human, and are useful as experimental animals.

Abstract: This invention relates to an anti-human thymidylate synthase monoclonal antibody capable of recognizing an epitope which exists in a region of 187th to 313th amino acids from an N-terminus in human thymidy late synthase, an anti-human thymidylate synthase monoclonal antibody capable of recognizing an epitope which exists in a region of from an N-terminus to a 61st amino acid in human thymidylate synthase, and also hybridomas capable of producing these monoclonal anti-bodies. These monoclonal antibodies are useful for the immunological measurement of human thymidylate synthase.

Abstract: The present invention provides an agent for alleviating side effects caused by use of an anti-tumor agent, which contains 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidi nedione (1) represented by formula (1): or a pharmaceutically acceptable salt thereof. The 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof exhibit an inflammatory-suppressing action in the digestive tract and advantageously alleviate diarrhea and loss of body weight concomitant with administration of a chemical for treating cancer without suppressing the anti-tumor effect. Thus, the compounds of the present invention are of great value as agents for alleviating side effects caused by use of an anti-tumor agent, which enable not only the chemotherapy to be continuedly carried out, but also the body exhaustion to be effectively prevented.

Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects on human derived thymidine phosphorylates and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators and antitumor agents containing such novel compounds, and a process for their preparation and use are described.

Abstract: An AC surface discharge plasma display panel and a method for driving the same are provided. In the method for driving the AC surface discharge plasma display panel according to the present invention, a parallel driving method is used, which is known to have better brightness characteristics than a separate driving method in which the addressing is separate from the discharge sustaining, in which the addressing and discharge sustaining are simultaneously performed. Periods between the discharge sustaining pulses applied to the scanning electrodes and the common electrodes are set as the address time slots periods, a plurality of data pulses are applied in the address time slot periods, and a number of common electrodes equal to the number of data pulses are wired as one common electrode group and are driven by the same signal, in order to solve the restrictions on the number of the horizontal scanning lines which can be scanned, which is a defect of conventional parallel drive methods.

Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described.

Abstract: The invention relates to an agent for preventing and treating ulcerous colitis and/or Crohn's disease, comprising conagenin or a pharmaceutically acceptable salt thereof as an active ingredient. According to the present invention, there is provided an agent for preventing and treating ulcerous colitis and/or Crohn's disease, which has high therapeutic effect and safety.

Abstract: This invention relates to a thiazolidinedione derivative represented by the following formula (1): ##STR1## wherein R.sup.1 and R.sup.2 individually represent H, a halogen atom, or a halogen-substituted or -unsubstituted lower alkyl or alkoxy group, and R.sup.1 and R.sup.2 may be coupled together to form a ring of an alkylenedioxy chain, X represents a nitrogen atom or a CH group, A represents a substituted or unsubstituted imidazolidinone, pyrrolidinone, imidazole or pyrazole ring, or a salt thereof; and a pharmaceutical composition containing the thiazolidinedione derivative or a salt thereof. The above compound has excellent blood sugar-lowering action and blood lipid-lowering action and is useful as a therapeutic agent for diabetes.

Abstract: The compounds of the invention are a 2'-deoxy-5-fluorouridine derivative represented by the formula ##STR1## wherein one of R.sub.1 and R.sub.2 is a hydrogen atom or a group easily hydrolyzable in vivo, the other is a benzyl group which may optionally have at least one halogen atom or trifluoromethyl group as a substituent on the phenyl ring, and R.sub.3 is a lower alkyl group, and a pharmaceutically acceptable salt thereof.The compounds of the invention can be suitably used as an antitumor agent.

Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described.

Abstract: This invention provides a composition, method and kit for potentiating the antitumor effect of tegafur and reducing the side effects of tegafur, comprising a compound of the formula ##STR1## wherein X is a halogen atom or a cyano group and oxonic acid or a pharmaceutically acceptable salt thereof, and also provides a composition, method and kit for treating a tumor, comprising tegafur, a compound of the formula (I) and oxonic acid or a pharmaceutically acceptable salt thereof.

Abstract: A thiazolidine derivative represented by the following formula (1): ##STR1## X represents a carbon atom or nitrogen atom, Y represents an oxygen atom or an imino group; A and B individually represent a lower alkylene group, m stands for 0 or 1, and a method of treatment of diabetes by administration of the compound.